Taylor Wessing Advises Cumulus Oncology on GPR68 Collaboration
Exclusive Licence and Development Collaboration with leadXpro
International law firm Taylor Wessing has successfully advised Cumulus Oncology, a clinical-stage oncology company developing radiopharmaceuticals targeting cancer, on its exclusive worldwide licence and development collaboration agreement with leadXpro, a radiopharmaceutical company.
Under the terms of the agreement, leadXpro has granted Cumulus Oncology an exclusive worldwide licence to develop and commercialise leadXpro's novel prostate-specific membrane antigen (PSMA)-targeted radioligand, [177Lu]Lu-PSMA-617, for use in the treatment of prostate cancer.
Transaction Highlights
- Taylor Wessing advised Cumulus Oncology on all aspects of the transaction, including negotiation of the licence agreement, regulatory and compliance matters, and intellectual property.
- The transaction closed on 31 March 2023.
- The Taylor Wessing team was led by Life Sciences & Healthcare partner Simon Burns, with support from senior associate Alice Collett and associate Katie Ayres.
About Cumulus Oncology
Cumulus Oncology is a clinical-stage oncology company developing a pipeline of radiopharmaceuticals targeting cancer. The company's lead product candidate, [177Lu]Lu-PSMA-617, is a PSMA-targeted radioligand that has shown promising results in clinical trials for the treatment of prostate cancer.
About leadXpro
leadXpro is a radiopharmaceutical company focused on the development of innovative radioligands for the treatment of cancer. The company's lead product candidate, [177Lu]Lu-PSMA-617, is a PSMA-targeted radioligand that has shown promising results in clinical trials for the treatment of prostate cancer.
Taylor Wessing is a leading international law firm with a focus on the technology, media, telecommunications, and life sciences sectors. The firm has a team of experienced life sciences lawyers who advise clients on a wide range of matters, including licensing, regulatory compliance, and intellectual property.
Komentar